Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy

9 Jan 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Cancer Treatment Studies
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33423006
DOI: 10.1016/j.ejca.2020.12.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapyPMID 33423006Read ↗

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsSemantic proximity Read ↗

The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.Semantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.Semantic proximity Read ↗

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.Semantic proximity Read ↗

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSemantic proximity Read ↗

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.Semantic proximity Read ↗

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer ChemotherapySemantic proximity Read ↗

BRCA2 mutation and the risk of hematologic malignancy.Semantic proximity Read ↗

Efficacy and Toxicity of Neoadjuvant Chemotherapy versus Chemo-immunotherapy in Triple-Negative Breast Cancer Patients with and without Germline BRCA MutationsSemantic proximity Read ↗

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1Semantic proximity Read ↗

Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.